Welcome!

News Feed Item

Stockholder Rights Plan, Quarterly Results, Clinical Trial Results, Purchase Agreements, and New Contracts - Analyst Notes on Allergan, Gilead, Pfizer, Actavis and Express Scripts

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, April 25, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Allergan, Inc. (NYSE: AGN), Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT) and Express Scripts Holding Company (NASDAQ: ESRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1586-100free.

--
Allergan, Inc. Analyst Notes
On April 22, 2014, Allergan, Inc. (Allergan) announced that its Board of Directors has unanimously adopted a one-year stockholder rights plan, effective on the day of the announcement, and has declared a dividend distribution of one preferred share purchase right on each outstanding share of the Company's common stock. The Company informed that under the plan, stockholders of record at the close of business on May 8, 2014 will receive one right for each share of Allergan common stock held on that date. Allergan informed that the plan is expected to expire on April 22, 2015. The full analyst notes on Allergan are available to download free of charge at:

http://www.analystsreview.com/1586-AGN-25Apr2014.pdf

--
Gilead Sciences, Inc. Analyst Notes
On April 22, 2014, Gilead Sciences, Inc. (Gilead) reported Q1 2014 financial results. During the quarter, the Company's total revenues increased to c. $5 billion from $2.5 billion in Q1 2013. Q1 2014 net income attributable to Gilead was $2.2 billion, or $1.33 per diluted share, compared to $722.2 million, or $0.43 per diluted share, in Q1 2013. Q1 2014 non-GAAP net income attributable to the Company was $2.5 billion, or $1.48 per diluted share, compared to $801.9 million, or $0.48 per diluted share, in Q1 2013. The Company reiterated its full-year 2014 guidance with net product sales expected to range from $11.3 billion - $11.5 billion. The full analyst notes on Gilead are available to download free of charge at:

http://www.analystsreview.com/1586-GILD-25Apr2014.pdf

--
Pfizer Inc. Analyst Notes
On April 22, 2014, Pfizer Inc. (Pfizer) announced top-line results from OPT Pivotal #1, and OPT Pivotal #2 Phase 3 trials from the oral treatment psoriasis trials (OPT) Program, evaluating the efficacy and safety of tofacitinib. The Company informed that OPT Pivotal #1 and OPT Pivotal #2 studies demonstrated that tofacitinib, as a 5mg or a 10mg dose taken as a pill twice-daily, met the primary efficacy endpoints of statistically significant superiority over placebo at Week 16 in the proportion of subjects achieving a Physician's Global Assessment response of "clear" or "almost clear," and the proportion of subjects achieving at least a 75% reduction in Psoriasis Area and Severity Index. The Company informed that it intends to submit a supplemental New Drug Application to the U.S. Food and Drug Administration for the approval of tofacitinib 5mg and 10mg twice-daily for treating adults with moderate-to-severe chronic plaque psoriasis by early 2015. The full analyst notes on Pfizer are available to download free of charge at:

http://www.analystsreview.com/1586-PFE-25Apr2014.pdf

--
Actavis plc Analyst Notes
On April 17, 2014, Actavis plc (Actavis) announced that it has entered into agreements with Akorn, Inc. (Akorn) and Hi-Tech Pharmacal Co. (Hi-Tech Pharmacal), in order to purchase four currently marketed products and one product under development for cash consideration. Actavis informed that the closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech Pharmacal. "The acquisition of these products will complement our expanding portfolio of topical and ophthalmic generic products, and further strengthen our position as a leader in developing and marketing the complex, high-barrier products that provide enhanced value," commented Siggi Olafsson, President of Actavis. The full analyst notes on Actavis are available to download free of charge at:

http://www.analystsreview.com/1586-ACT-25Apr2014.pdf

--
Express Scripts Holding Company Analyst Notes
On April 18, 2014, Express Scripts Holding Company (Express Scripts) reported that the U.S. Department of Defense has awarded the Company administration of the TRICARE Pharmacy Program, Fourth Generation (TPharm4) contract serving approximately 10 million beneficiaries. Express Scripts informed that the seven-year contract includes administering a retail pharmacy network, operating the TRICARE Mail Order Pharmacy and providing specialty pharmacy services, effective May 1, 2015. The full analyst notes on Express Scripts are available to download free of charge at:

http://www.analystsreview.com/1586-ESRX-25Apr2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


http://AnalystsReview.com

 

SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Businesses and business units of all sizes can benefit from cloud computing, but many don't want the cost, performance and security concerns of public cloud nor the complexity of building their own private clouds. Today, some cloud vendors are using artificial intelligence (AI) to simplify cloud deployment and management. In his session at 20th Cloud Expo, Ajay Gulati, Co-founder and CEO of ZeroStack, will discuss how AI can simplify cloud operations. He will cover the following topics: why clou...
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lead...
"Qosmos has launched L7Viewer, a network traffic analysis tool, so it analyzes all the traffic between the virtual machine and the data center and the virtual machine and the external world," stated Sebastien Synold, Product Line Manager at Qosmos, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Internet-of-Things discussions can end up either going down the consumer gadget rabbit hole or focused on the sort of data logging that industrial manufacturers have been doing forever. However, in fact, companies today are already using IoT data both to optimize their operational technology and to improve the experience of customer interactions in novel ways. In his session at @ThingsExpo, Gordon Haff, Red Hat Technology Evangelist, will share examples from a wide range of industries – includin...
Kubernetes is a new and revolutionary open-sourced system for managing containers across multiple hosts in a cluster. Ansible is a simple IT automation tool for just about any requirement for reproducible environments. In his session at @DevOpsSummit at 18th Cloud Expo, Patrick Galbraith, a principal engineer at HPE, discussed how to build a fully functional Kubernetes cluster on a number of virtual machines or bare-metal hosts. Also included will be a brief demonstration of running a Galera MyS...
The WebRTC Summit New York, to be held June 6-8, 2017, at the Javits Center in New York City, NY, announces that its Call for Papers is now open. Topics include all aspects of improving IT delivery by eliminating waste through automated business models leveraging cloud technologies. WebRTC Summit is co-located with 20th International Cloud Expo and @ThingsExpo. WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web co...
"We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We analyze the video streaming experience. We are gathering the user behavior in real time from the user devices and we analyze how users experience the video streaming," explained Eric Kim, Founder and CEO at Streamlyzer, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"This is specifically designed to accommodate some of the needs for high availability and failover in a network managed system for the major Korean corporations," stated Thomas Masters, Managing Director at InfranicsUSA, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Enterprise IT has been in the era of Hybrid Cloud for some time now. But it seems most conversations about Hybrid are focused on integrating AWS, Microsoft Azure, or Google ECM into existing on-premises systems. Where is all the Private Cloud? What do technology providers need to do to make their offerings more compelling? How should enterprise IT executives and buyers define their focus, needs, and roadmap, and communicate that clearly to the providers?
"We are an all-flash array storage provider but our focus has been on VM-aware storage specifically for virtualized applications," stated Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We are a leader in the market space called network visibility solutions - it enables monitoring tools and Big Data analysis to access the data and be able to see the performance," explained Shay Morag, VP of Sales and Marketing at Niagara Networks, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
According to Forrester Research, every business will become either a digital predator or digital prey by 2020. To avoid demise, organizations must rapidly create new sources of value in their end-to-end customer experiences. True digital predators also must break down information and process silos and extend digital transformation initiatives to empower employees with the digital resources needed to win, serve, and retain customers.
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
Organizations planning enterprise data center consolidation and modernization projects are faced with a challenging, costly reality. Requirements to deploy modern, cloud-native applications simultaneously with traditional client/server applications are almost impossible to achieve with hardware-centric enterprise infrastructure. Compute and network infrastructure are fast moving down a software-defined path, but storage has been a laggard. Until now.